Advertisement

The Metabolic Syndrome

  • Scott M. Grundy
Chapter

Abstract

The National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) report [1] added the metabolic syndrome, a multidimensional risk factor for cardiovascular disease (CVD), as a coequal partner of elevated low-density lipoprotein (LDL) cholesterol for risk-reduction therapies. Interest in the metabolic syndrome has increased greatly since the publication of the ATP III report. There are several aspects to the metabolic syndrome that deserve consideration for clinical practice: 1) major clinical outcomes, 2) metabolic components, 3) pathogenesis, 4) clinical criteria for diagnosis, 5) risk for clinical outcomes, and 6) therapeutic interventions.

Keywords

Insulin Resistance Metabolic Syndrome Impaired Fasting Glucose Metabolic Risk Factor Insulin Resistance Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.Google Scholar
  2. 2.
    Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.CrossRefPubMedGoogle Scholar
  3. 3.
    Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991, 34:416–422.CrossRefPubMedGoogle Scholar
  4. 4.
    Abbasi F, Brown BW Jr, Lamendola C, et al.: Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002, 40:937–943.CrossRefPubMedGoogle Scholar
  5. 5.
    Bogardus C, Lillioja S, Mott DM, et al.: Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985, 248 (3 Pt 1):E286–E291.PubMedGoogle Scholar
  6. 6.
    Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539–553.CrossRefPubMedGoogle Scholar
  7. 7.
    Einhorn D: ACE position statement on insulin resistance syndrome. Endocr Pract 2003, 9:237–252.PubMedGoogle Scholar
  8. 8.
    Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752CrossRefPubMedGoogle Scholar
  9. 9.
    Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome—a new worldwide definition. Lancet 2005, 366:1059–1062.CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenzweig JL, Ferrannini E, Grundy SM, et al.: Endocrine Society. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3671–3689.CrossRefPubMedGoogle Scholar
  11. 11.
    Alberti KG, Eckel RH, Grundy SM, et al.: Harmonizing the Metabolic Syndrome. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640–1645.CrossRefPubMedGoogle Scholar
  12. 12.
    Grundy SM, Brewer HB Jr, Cleeman JI, et al.: American Heart Association; National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433–438.CrossRefPubMedGoogle Scholar
  13. 13.
    Rubins HB: Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk 2000, 7:339–345.PubMedGoogle Scholar
  14. 14.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.CrossRefPubMedGoogle Scholar
  15. 15.
    Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968–977.PubMedGoogle Scholar
  16. 16.
    Engfeldt P, Arner P: Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl 1988, 19:26–29.PubMedGoogle Scholar
  17. 17.
    Olefsky JM: Insensitivity of large rat adipocytes to the antilipolytic effects of insulin. J Lipid Res 1977, 18:459–464.PubMedGoogle Scholar
  18. 18.
    Gruen R, Kava R, Greenwood MR: Development of basal lipolysis and fat cell size in the epididymal fat pad of normal rats. Metabolism 1980, 29:246–253.CrossRefPubMedGoogle Scholar
  19. 19.
    Ek I, Arner P, Ryden M, et al.: A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 2002, 51:484–492.CrossRefPubMedGoogle Scholar
  20. 20.
    Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.PubMedGoogle Scholar
  21. 21.
    Garg A: Acquired and inherited lipodystrophies. N Engl J Med 2004, 350:1220–1234.CrossRefPubMedGoogle Scholar
  22. 22.
    Jensen MD: Health consequences of fat distribution. Horm Res 1997, 48(Suppl 5):88–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Guerre-Millo M: Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004, 30:13–19.CrossRefPubMedGoogle Scholar
  24. 24.
    Muoio DM, Lynis Dohm G: Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002, 16:653–666.CrossRefPubMedGoogle Scholar
  25. 25.
    Garg A, Misra A: Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004, 33:305–331.CrossRefPubMedGoogle Scholar
  26. 26.
    Lind L: Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003, 169:203–214.CrossRefPubMedGoogle Scholar
  27. 27.
    Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003, 1:1575–1579.CrossRefPubMedGoogle Scholar
  28. 28.
    Miller GJ: Lipoproteins and the haemostatic system in athero­thrombotic disorders. Baillieres Best Pract Res Clin Haematol 1999, 12:555–575.PubMedGoogle Scholar
  29. 29.
    Steppan CM, Lazar MA: The current biology of resistin. J Intern Med 2004, 255:439–447.CrossRefPubMedGoogle Scholar
  30. 30.
    Trujillo ME, Scherer PE: Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005, 257:167-75CrossRefPubMedGoogle Scholar
  31. 31.
    Le Roith D, Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001, 24:588–97.CrossRefPubMedGoogle Scholar
  32. 32.
    Randle PJ, Priestman DA, Mistry S, Halsall A: Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 1994, 37(Suppl 2):S155–S161.CrossRefPubMedGoogle Scholar
  33. 33.
    Savage DB, Petersen KF, Shulman GI: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005, 45:828–833CrossRefPubMedGoogle Scholar
  34. 34.
    Petersen KF, Befroy D, Dufour S, et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300: 1140–1142.CrossRefPubMedGoogle Scholar
  35. 35.
    Lake S, Krook A, Zierath JR: Analysis of insulin signaling pathways through comparative genomics. Mapping mechanisms for insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus. Exp Clin Endocrinol Diabetes 2003, 111:191–197.CrossRefPubMedGoogle Scholar
  36. 36.
    Saltiel AR, Pessin JE: Insulin signaling in microdomains of the plasma membrane. Traffic 2003, 4:711–716.CrossRefPubMedGoogle Scholar
  37. 37.
    Ruderman NB, Dean D: Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. J Basic Clin Physiol Pharmacol 1998, 9:295–308.PubMedGoogle Scholar
  38. 38.
    Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14–23.CrossRefPubMedGoogle Scholar
  39. 39.
    Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171–176.CrossRefPubMedGoogle Scholar
  40. 40.
    Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S53–S55.CrossRefPubMedGoogle Scholar
  41. 41.
    Lee YH, White MF: Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004, 27:361–370.CrossRefPubMedGoogle Scholar
  42. 42.
    Frittitta L, Baratta R, Spampinato D, et al.: The Q121 PC-1 variant and obesity have additive and independent effects in causing insulin resistance. J Clin Endocrinol Metab 2001, 86:5888–5891.CrossRefPubMedGoogle Scholar
  43. 43.
    Abate N, Carulli L, Cabo-Chan A Jr, et al.: Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab 2003, 88:5927–5934.CrossRefPubMedGoogle Scholar
  44. 44.
    Abate N, Chandalia M, Di Paola R, et al.: Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a ’gatekeeper’ of insulin receptors. Nat Clin Pract Endocrinol Metab 2006, 2:694–701.CrossRefPubMedGoogle Scholar
  45. 45.
    Diraison F, Moulin P, Beylot M: Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003, 29:478–485.CrossRefPubMedGoogle Scholar
  46. 46.
    Grundy SM: Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am J Clin Nutr 2004, 80:1–2.PubMedGoogle Scholar
  47. 47.
    Nie L, Wang J, Clark LT, et al.: Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res 1998, 39:1127–1130.PubMedGoogle Scholar
  48. 48.
    Egusa G, Beltz WF, Grundy SM, Howard BV: Influence of obesity on the metabolism of apolipoprotein B in humans. J Clin Invest 1985, 76:596–603.CrossRefPubMedGoogle Scholar
  49. 49.
    Kesaniemi YA, Beltz WF, Grundy SM: Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. J Clin Invest 1985, 76:586–595.CrossRefPubMedGoogle Scholar
  50. 50.
    McGarry JD: Glucose-fatty acid interactions in health and disease. Am J Clin Nutr 1998, 67(3 Suppl):500S–504S.PubMedGoogle Scholar
  51. 51.
    Shimomura I, Matsuda M, Hammer RE, et al.: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000, 6:77–86.CrossRefPubMedGoogle Scholar
  52. 52.
    Schwarz JM, Linfoot P, Dare D, Aghajanian K: Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003, 77:43–50.PubMedGoogle Scholar
  53. 53.
    Hudgins LC, Hellerstein MK, Seidman CE, et al.: Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res 2000, 41:595–604.PubMedGoogle Scholar
  54. 54.
    Sidossis LS, Mittendorfer B, Walser E, et al.: Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Am J Physiol 1998, 275(5 Pt 1):E798–E805.PubMedGoogle Scholar
  55. 55.
    Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome Among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.CrossRefPubMedGoogle Scholar
  56. 56.
    Hedley AA, Ogden CL, Johnson CL, et al.: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004, 291:2847–2850.CrossRefPubMedGoogle Scholar
  57. 57.
    Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18B–25B.CrossRefPubMedGoogle Scholar
  58. 58.
    Krauss RM, Siri PW: Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am 2004, 33: 405–415.CrossRefPubMedGoogle Scholar
  59. 59.
    Carr MC, Ayyobi AF, Murdoch SJ, et al.: Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 2002, 22:667–673.CrossRefPubMedGoogle Scholar
  60. 60.
    Grundy SM, Vega GL, Otvos JD, et al.: Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence. J Lipid Res 1999, 40:229–234.PubMedGoogle Scholar
  61. 61.
    Hall JE: The kidney, hypertension, and obesity. Hypertension 2003, 41(3 Pt 2):625–633.CrossRefPubMedGoogle Scholar
  62. 62.
    Hall JE: Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000, 2:139–147.CrossRefPubMedGoogle Scholar
  63. 63.
    Sesso HD, Buring JE, Rifai N, et al.: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945–2951.CrossRefPubMedGoogle Scholar
  64. 64.
    De Pergola G, Pannacciulli N: Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002, 25:899–904.PubMedGoogle Scholar
  65. 65.
    Vague P, Raccah D, Scelles V: Hypofibrinolysis and the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995, 19(Suppl 1): S11–S15.PubMedGoogle Scholar
  66. 66.
    Freeman MS, Mansfield MW, Barrett JH, Grant PJ: Insulin resistance: an atherothrombotic syndrome. The Leeds family study. Thromb Haemost 2003, 89:161–168.PubMedGoogle Scholar
  67. 67.
    Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391–397.CrossRefPubMedGoogle Scholar
  68. 68.
    Pearson TA, Mensah GA, Alexander RW, et al.: Centers for Disease Control and Prevention; American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.CrossRefPubMedGoogle Scholar
  69. 69.
    Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:2818–2825.CrossRefPubMedGoogle Scholar
  70. 70.
    Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.CrossRefGoogle Scholar
  71. 71.
    Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—The Evidence Report. National Institutes of Health. Obes Res 1998, 6(Suppl 2):51S–209S.Google Scholar
  72. 72.
    Grundy SM, Cleeman JI, Merz CN, et al.: National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.CrossRefPubMedGoogle Scholar
  73. 73.
    Chobanian AV, Bakris GL, Black HR, et al.: National Heart Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation; National High Blood Pressure Education Program Coordinating Committee: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.CrossRefPubMedGoogle Scholar
  74. 74.
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002, 25(Suppl 1):S1–S147.Google Scholar
  75. 75.
    Pearson TA, Blair SN, Daniels SR, et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388–391.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Scott M. Grundy
    • 1
  1. 1.Internal Medicine Nutrition and Metabolic DiseasesUniversity of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations